More interestingly, Bitler et al. demonstrated that EZH2 inhibitor, GSK126, acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells and that ARID1A mutational status correlated with response to the EZH2 inhibitor [210]. The gene discussed is EZH2; the disease is ovarian cancer.